The drama of the FDA’s approval of Biogen’s Aduhelm is far from over. But what happens next? Read More
Related Articles
The Issue with VC-backed Creators who State That They do Not care about Becoming Wealthy
The firm named following the folktale–that the decacorn stock trading program Robinhood–is in the middle of a identity crisis as critics accuse the business of giving their ancestral origins in favour of hyper-growth. While its creators might not have sought to become wealthy, they’re still very likely to become billionaires when Robinhood moves people, and […]
U.K. antitrust probe targets Google Chrome privacy changes
Google has a habit of inviting regulatory scrutiny on both privacy and antitrust fronts, so why not both at once? On Friday, the U.K.’s competition watchdog opened a formal investigation into Google over supposedly pro-privacy changes the company is making to its market-leading Chrome browser. The government group said it will review whether the proposed […]
The Greatest tech news That You missed Thanksgiving
I am happy to return from Thanksgiving break, once I eventually gave up trying to enjoy turkey and picked for lasagna. Similar to lasagna (forgive the pun), the information layered on within the extended U.S. vacation as investors chose to make the most of those odd market requirements to IPO or combine with other companies. […]